Palatin presents preclinical data for PL9588 glaucoma candidate at ARVO; shows IOP reduction in rabbits

PALATIN TECHNOLOGIES INC

Topically administered PL9588 reduced intraocular pressure (IOP) in normotensive rabbits.
IOP reduction magnitude similar or greater than FDA-approved drugs latanoprost and timolol.
Single topical dose of PL9588 lowered IOP for 24 hours.
PL9588 is a melanocortin agonist; data supports continued development for once-daily glaucoma treatment.
Company plans to move into clinical development pending available resources.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.